In Brief: Guidant
This article was originally published in The Gray Sheet
Executive SummaryGuidant: Commences clinical trial of its coronary intravascular radiotherapy system for reduction of restenosis following interventional cardiology procedures Oct. 28 at the Methodist Hospital of Baylor College in Houston, Texas. Guidant received investigational device exemption approval in September to begin the PREVENT trial (Proliferation Reduction with Vascular Energy Trial), which will also take place at the Thoraxcentre in Rotterdam, The Netherlands and the Northern General Hospital in Sheffield, U.K. The radiotherapy system consists of a flexible source wire with a radioactive isotope in its tip, a source delivery unit and a centering catheter, through which the source wire is placed...
You may also be interested in...
As the coronavirus continues to spread, one of the big four global vaccines companies has committed itself to the fight.
Sweden’s mid-sized pharmaceutical company, Swedish Orphan Biovitrum, has expanded into hematology and strengthened its immunology business, growing its top and bottom lines in 2019.
An AAM-sponsored study by researcher Avalere Health has concluded that Medicare Part D policy changes have led to generics being placed on non-generic tiers 53% of the time in 2020, with generics placed on the ‘preferred generic’ Tier 1 just 10% of the time.